It was .002 bottom for 18 months, and was thin to .01 the entire time, with no volume for 18 months. The OS is now about 245,000 shares rounded off. R/S with the R/M was 500:1 R/S.
They paid off debt before the R/S with shares that also got R/S.
The group that got those shares for cash to pay off the debt own about 48% of the float now.
I own 1%. I will buy more under $4 if I get the chance. It is my hope that they will pump the stock to $20 before any float dilution or even before raising cash. They have a complex share structure, multiple preferred share classes. It was structured to raise cash for acquisitions of university biotech patents....and to be operated like a public, venture capital incubator bridge funding firm.
I should add that the Spotlight investors that bought AEXP in the R/M (my guess is that is the CEO), got about 7.5 million restricted shares, that are not in the float.
So if they get the stock to $10/share with news, that gives it a 75 Mil $ market cap to raise private biotech investor funds. :-)
News 
Market Data 
Discover 
